Immune system stimulation via tumor-associated antigens

Immune system stimulation via tumor-associated antigens refers to therapeutic strategies that harness the immune system to recognize and attack cancer cells by targeting antigens abnormally or highly expressed on tumor cells (tumor-associated antigens, TAAs). These antigens, though present in some normal tissues, can elicit an immune response when presented in the context of cancer. Clinical approaches include cancer vaccines, adoptive cell therapies, and antibody-based therapies designed to enhance T-cell recognition and killing of tumor cells. However, because TAAs are not always entirely tumor-specific and may be expressed in certain normal tissues, targeting them carries a risk of off-tumor effects and autoimmunity. This strategy is foundational to many immunotherapies currently under investigation and in clinical use, but it does not refer to a discrete molecular target like a defined receptor or enzyme[4][5]. "Tumor-associated antigens" are not unique to tumor cells; they are often normal self-antigens over-expressed or aberrantly modified in cancer[5]. Immunotherapies leveraging TAAs include peptide and protein vaccines, dendritic cell vaccines, antibody therapies, and adoptive cell transfer[4][5]. Examples of well-studied TAAs include MAGE (melanoma-associated antigen), AFP (alphafetoprotein), and PSA (prostate-specific antigen)[5]. The immune reaction involves both innate and adaptive arms: professional antigen-presenting cells (APCs), T lymphocytes (CD8+ and CD4+), and co-stimulatory signals are crucial for effective anti-tumor immunity[2][3][6]. Challenges include immune tolerance, tumor-induced immunosuppression, and risks of attacking non-cancer tissues due to antigen overlap[2][4]. In summary, "Immune system stimulation via tumor-associated antigens" describes a therapeutic strategy and is not a canonical single molecular target[5][4]. This entry is flagged as is_incorrect:true for canonical target listings.

Other names

Tumor immune stimulation via TAAImmune activation by tumor-associated antigensTAA-driven immune modulation

Induction of tumor-specific immunity, Activation of adaptive immune response against tumor, Breaking immune tolerance to tumor antigens